A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Muralidhar Beeram, MD
The START Center for Cancer Care
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Southern California Norris Comprehensive Cancer Center
Los Angeles, California, United States
- Indiana University (iupui)
Indianapolis, Indiana, United States
- Fox Chase Center
Philadelphia, Pennsylvania, United States
- South Texas Accelerated Research Therapeutics
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2009
- Primary completion
- 31 Mar 2012
- Completion
- 31 Mar 2012
- Last update posted
- 13 Jan 2015
- Registered enrollment
- 20
- Registry id
- NCT00911898
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.